KSKayte Spector-Bagdady

Kayte Spector-Bagdady

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Kayte Spector-Bagdady has a total of 108 co-authors. Here are the top co-authors by number of shared publications:

  • Kaitlyn Jaffe

    Department of Health Promotion and Policy, University of Massachusetts Amherst, 715 North Pleasant Street, Amherst, MA 01003, United States; BC Centre on Substance Use, 400-1045 Howe Street, Vancouver, BC V6Z 2A9, Canada

    5 shared publications
  • Chris D. Krenz

    Boston University, Boston, Massachusetts, USA

    4 shared publications
  • J. Denard Thomas

    Center for Bioethics & Social Sciences in Medicine, University of Michigan Medical School

    4 shared publications
  • J. Scott Roberts

    Center for Bioethics & Social Sciences in Medicine, University of Michigan Medical School

    4 shared publications
  • Kerry A. Ryan

    Center for Bioethics & Social Sciences in Medicine, University of Michigan Medical School

    4 shared publications
  • Amy L. McGuire

    Baylor College of Medicine, Houston, Texas, USA

    3 shared publications

Latest Publications

  • Open Access

    Identifying "Identifiability:" From Regulatory Illusions to Techno-normative Frameworks to Protect Health Data Privacy

    by Kayte Spector-Bagdady, Jeremy Seeman, Steven Marcus, Donovan Maust

    The foundational assumption underlying U.S. health data governance – that data are either "identified" and protected or "de-identified" and unregulated – is both legally incoherent and technically obsolete. Enacted when de-identification seemed a plausible safeguard, the HIPAA Privacy Rule codified this binary into law. HIPAA offers two de-identification pathways: expert determination and the safe harbor method. Institutional incentives have driven near-universal adoption of the safe harbor, producing , a form of legal endogeneity in which symbolic compliance with the eighteen HIPAA enumerated identifiers became mistaken for substantive privacy protection. The Common Rule's divergent identifiability definition has compounded this incoherence, and recent NIH attempts to contractually harmonize these conflicting standards represent regulatory surrender rather than reform.Re-identifiability is not a binary condition but a multi-dimensional, temporally shifting continuum shaped by the availability of external key data, evolving adversarial capabilities (including machine learning and AI), and the motivation of those seeking privacy breaches. Re-identification risk is also distributed inequitably, falling disproportionately on minoritized populations and individuals with rare conditions – precisely those whose data hold the greatest potential for advancing health equity. The binary regulatory framework not only fails to address this heterogeneity but actively reproduces its structural inequities.Drawing on Lessig's theory of regulatory modalities, we argue that privacy governance is an architectural problem as much as a legal one. Effective governance must redesign the architecture of data systems, not merely update their legal labels. We review novel technical approaches including k-anonymity frameworks, tiered access systems, controlled-access enclaves, and context-responsive suppression. We then begin to elucidate what level of re-identification risk is ethically acceptable for what data. Critically, the achievement of "privacy" cannot be resolved by technical thresholds alone.We ground these arguments in our experience designing the National Dementia Workforce Study (NDWS) secure data enclave, contrasting our approach with the All of Us Research Program. Both cases demonstrate that meaningful expert determination already occurs through iterative, multidisciplinary deliberation among lawyers, bioethicists, data scientists, and community representatives, and not through fixed methodologies.Federal regulators need not undertake the Sisyphean task of overhauling HIPAA to begin meaningful reform. What is required is a deliberate shift away from safe harbor compliance as a default, toward ML-enabled expert determination-grounded governance frameworks as adaptive and equitable as the risks they govern.

  • Open Access

    Uncovered, underfunded, and undervalued: How policy contexts shape knowledge production in multi-site substance use trials

    by Kaitlyn Jaffe, Didier Jutras-Aswad, Kayte Spector-Bagdady, Lindsey Richardson

  • Open Access

    Differences Between Government, Consortium, and Private Database Stewards Impacting the Genomic Data Market: A Survey of U.S. Academic Genetic Researchers

    by Amanda K. Greene, J. Denard Thomas, Kaitlyn Jaffe, Luyun Chen, Kerry A. Ryan, Brian J. Zikmund-Fisher, J. Scott Roberts, Amy L. McGuire, Katherine Hendy, Kayte Spector-Bagdady

    Despite major shifts in U.S. federal government data sharing requirements, their impact, and relation to researcher choice of database, are underexplored. This study surveyed genetic researchers regarding trends, priorities, perceptions of quality, impact on research outcomes, and genomic data sharing and use across government, consortium, and private databases. As part of an exploratory sequential mixed methods project, we surveyed 294 U.S.-based genomic academic researchers. Genetic researchers generally have a choice between databases, which allows them to prioritize data quality. This might explain recent trends toward the use of government and consortium databases away from private ones. Respondents reported several significant differences in the requirements that different data stewards place on them, which impact their work. Private data stewards generally had the most restrictions and were the least likely to allow users to release the full dataset at completion, despite over 50% of respondents reporting the use of federal funds for such research. Our findings indicate that upstream benefits (i.e., access, database features) are more impactful on researchers' choice in databases than downstream publication limitations (e.g., co-authorship, limited data release). Respondents also reported the time necessary to share data as the biggest barrier to contributing to government databases and non-comprehensiveness as the biggest challenge to using existing government data. The federal government can leverage these findings about researcher priorities to continue attracting researchers, to push forward goals related to open science and enabling advances for patients underrepresented in genetic research, and to found new genomic data sharing policy moving forward.


  • Open Access

    Putting the L in ELSI: legal methods for bioethics research

    by Anya E R Prince, Benjamin Berkman, Donald Ford, Dov Fox, Christi Guerrini, Amy Koopmann, Natalie Ram, Jessica L Roberts, Kayte Spector-Bagdady, Sonia Suter

    Lawyers and law professors are increasingly involved in interdisciplinary scientific teams and grant research to answer ethical, legal and policy questions related to biomedical topics. Yet, the methods that lawyers use to conduct legal research and analysis are not always familiar to scientists and social scientists conducting peer review of a proposed project with legal aims or a publication reporting a legal study. To better facilitate interdisciplinary ethical, legal, and social implications collaboration, there is a need to better explain how legal research methodologies can provide robust tools to address a range of nuanced biomedical questions. This paper explores legal research and analysis methodologies relevant to federally funded research and scientific inquiry. It sets out different ways that legal research and analysis can advance and support biomedical, bioethics, and health law research and then demonstrates how these benefits can be realized using case studies from existing literature.

  • Open Access

    The Genetic Data Market: Institutional Governance of Academic/Industry Research Partnerships for the Public Good

    by Kayte Spector-Bagdady

    The Trump Administration's cuts to research funding and opposition to diversity, equity, and inclusion is destabilizing academic research. These attacks coincide with pointed government support for the private sector. But the conceptualization of academic versus private sector health research has historically been a false binary. Drawing on mixed methods research, this paper examines the genomic data market as an example of advantages and challenges of commercializing academic expertise. It also highlights the structural downsides of researchers individually navigating industry partnerships. While academia is currently being put in the unenviable position of being more likely to need the private sector to conduct research, with less federal funding to offer in exchange, structural pain points have existed for decades. This is an opportunity for academia to harness its powers of expertise and collective action to develop institutional policy to ensure academic/industry research is beneficial to the public health and diverse patient communities.


  • Open Access

    The Need for Prospective Integrity Standards for the Use of Generative AI in Research

    by Kayte Spector-Bagdady

    The federal government has a long history of trying to find the right balance in supporting scientific and medical research while protecting the public and other researchers from potential harms. To date, this balance has been generally calibrated differently across contexts – including in clinical care, human subjects research, and research integrity. New challenges continue to face this disparate model of regulation, including novel Generative Artificial Intelligence (GenAI) tools. Because of potential increases in unintentional fabrication, falsification, and plagiarism using GenAI – and challenges establishing both these errors and intentionality in retrospect – this article argues that we should instead move toward a system that sets accepted community standards for the use of GenAI in research as prospective requirements.


  • Protecting Privacy When Genetic Databases Are Commercialized

    by Anya E. R. Prince, Kayte Spector-Bagdady

    This Viewpoint questions whether people’s health data obtained in direct-to-consumer genetic testing can be used, shared, or marketed in the future.


  • Open Access

    “A Double-Edged Sword”: A Brief History of Genomic Data Governance and Genetic Researcher Perspectives on Data Sharing

    by Kayte Spector-Bagdady, Kerry A. Ryan, Amy L. McGuire, Chris D. Krenz, M. Grace Trinidad, Kaitlyn Jaffe, Amanda Greene, J. Denard Thomas, Madison Kent, Stephanie Morain, et al.

    As the federal government continues to expand upon and improve its data sharing policies over the past 20 years, complex challenges remain. Our interviews with U.S. academic genetic researchers (n=23) found that the burden, translation, industry limitations, and consent structure of data sharing remain major governance challenges.


  • Open Access

    Lessons for a learning health system: Effectively communicating to patients about research with their health information and biospecimens

    by Kayte Spector‐Bagdady, Kerry A. Ryan, Luyun Chen, Camille Giacobone, Reshma Jagsi, Reema Hamasha, Katherine Hendy, J. Denard Thomas, Jessie M. Milne, Alexandra H. Vinson, et al.

    Introduction: Sharing patient health information and biospecimens can improve health outcomes and accelerate breakthroughs in medical research. But patients generally lack understanding of how their clinical data and biospecimens are used or commercialized for research. In this mixed methods project, we assessed the impact of communication materials on patient understanding, attitudes, and perceptions.Methods: Michigan Medicine patients were recruited for a survey (n = 480) or focus group (n = 33) via a web‐based research study portal. The survey assessed the impact of mode of communication about health data and biospecimen sharing (via an informational poster vs. a news article) on patient perceptions of privacy, transparency, comfort, respect, and trust. Focus groups provided in‐depth qualitative feedback on three communication materials, including a poster, FAQ webpage, and a consent form excerpt.Results: Among survey respondents, the type of intervention (poster vs. news) made no statistically significant difference in its influence on any characteristic. However, 95% preferred that Michigan Medicine tell them about patient data and biospecimen research sharing versus hearing it from the news. Focus group participants provided additional insights, discussing values and perceptions of altruism and reciprocity, concerns about commercialization, privacy, and security; and the desire for consent, control, and transparency.Conclusion: Developing our understanding of patient data‐sharing practices and integrating patient preferences into health system policy, through this work and continued exploration, contributes to building infrastructure that can be used to support the development of a learning health system across hospital systems nationally.